1b/2

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

February 23, 2026 17:10 ET | Source: Kyntra Bio FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen…

4 hours ago